What is the share price of Bacil Pharma Ltd (BACPHAR) today?
The share price of BACPHAR as on 4th November 2026 is ₹17.65. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Bacil Pharma Ltd (BACPHAR) share?
The past returns of Bacil Pharma Ltd (BACPHAR) share are- Past 1 week: -13.01%
- Past 1 month: -36.96%
- Past 3 months: -10.54%
- Past 6 months: -68.30%
- Past 1 year: -43.41%
- Past 3 years: 111.38%
- Past 5 years: 120.90%
What are the peers or stocks similar to Bacil Pharma Ltd (BACPHAR)?
The peers or stocks similar to Bacil Pharma Ltd (BACPHAR) include:What is the market cap of Bacil Pharma Ltd (BACPHAR) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bacil Pharma Ltd (BACPHAR) is ₹25.05 Cr as of 4th November 2026.What is the 52 week high and low of Bacil Pharma Ltd (BACPHAR) share?
The 52-week high of Bacil Pharma Ltd (BACPHAR) is ₹61.80 and the 52-week low is ₹10.65.What is the PE and PB ratio of Bacil Pharma Ltd (BACPHAR) stock?
The P/E (price-to-earnings) ratio of Bacil Pharma Ltd (BACPHAR) is 16.06. The P/B (price-to-book) ratio is 1.01.Which sector does Bacil Pharma Ltd (BACPHAR) belong to?
Bacil Pharma Ltd (BACPHAR) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Bacil Pharma Ltd (BACPHAR) shares?
You can directly buy Bacil Pharma Ltd (BACPHAR) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Bacil Pharma Ltd
BACPHAR Share Price
BSE₹17.652.00% (-0.36)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
SIP
BACPHAR Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
BACPHAR Performance & Key Metrics
BACPHAR Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 1.01 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 43.84 | 5.87 | 0.49% |
BACPHAR Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BACPHAR Company Profile
Bacil Pharma is engaged in the business of manufacturing of pharmaceuticals, medicinal chemicals and botanical products.
PE Ratio
34.10
34.10
1Y Return
5.17%
5.17%
Buy Reco %
93.55
93.55
TORNTPHARM
PE Ratio
81.89
81.89
1Y Return
31.45%
31.45%
Buy Reco %
85.19
85.19
LAURUSLABS
PE Ratio
141.27
141.27
1Y Return
134.64%
134.64%
Buy Reco %
61.54
61.54
ZYDUSLIFE
PE Ratio
21.59
21.59
1Y Return
22.57%
22.57%
Buy Reco %
57.69
57.69
PE Ratio
27.28
27.28
1Y Return
13.56%
13.56%
Buy Reco %
67.74
67.74
BACPHAR Forecast
BACPHAR Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
BACPHAR
BACPHAR
Income
Balance Sheet
Cash Flow
Quarterly Normal View
BACPHAR Income Statement
BACPHAR Income Statement
Quarterly Normal View
| Quarter | jun 2026 | sep 2026 | ||
|---|---|---|---|---|
| Total Revenue | 0.09 | 0.09 | ||
Operating & Other expenses | 0.02 | 0.06 | ||
EBITDA | 0.07 | 0.03 | ||
| Depreciation/Amortization | 0.00 | 0.00 | ||
| PBIT | 0.07 | 0.03 | ||
| Interest & Other Items | 0.00 | 0.06 | ||
| PBT | 0.07 | -0.03 | ||
| Taxes & Other Items | 0.08 | 0.04 | ||
| Net Income | -0.01 | -0.07 | ||
| EPS | 0.22 | 0.06 |
BACPHAR Company Updates
BACPHAR Stock Peers
BACPHAR Past Performance & Peer Comparison
BACPHAR Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Bacil Pharma Ltd | 16.06 | 1.01 | — |
| Sun Pharmaceutical Industries Limited | 34.10 | 5.07 | 0.90% |
| Torrent Pharmaceuticals Ltd | 81.89 | 10.25 | 0.71% |
| Laurus Labs Ltd | 141.27 | 23.12 | 0.09% |
Compare valuation on ScreenerBACPHAR Stock Price Comparison
Compare BACPHAR with any stock or ETFCompare BACPHAR with any stock or ETF
BACPHAR
BACPHAR Holdings
BACPHAR Shareholdings
BACPHAR Promoter Holdings Trend
BACPHAR Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
BACPHAR Institutional Holdings Trend
BACPHAR Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 2.11%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
BACPHAR Shareholding Pattern
BACPHAR Shareholding Pattern
BACPHAR Shareholding History
BACPHAR Shareholding History
Foreign Institutions
smallcases containing BACPHAR stock
smallcases containing BACPHAR stock
Looks like this stock is not in any smallcase yet.
BACPHAR Events
BACPHAR Events
BACPHAR Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BACPHAR has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
BACPHAR Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
BACPHAR has not given any dividends in last 5 years
BACPHAR Dividends
BACPHAR Dividends
Hmm, looks like data is unavailable here. Please come back after some timeBACPHAR Stock News & Opinions
BACPHAR Stock News & Opinions
Articles & Videos
Corporate
Corporate
Bacil Pharma confirms compliance with SEBI regulations for securities dematerialisationBacil Pharma Limited informed the BSE Limited that it has received a certificate from Bigshare Services Pvt. Ltd., confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the period ended September 30, 2026, pertaining to securities dematerialised and listed on stock exchanges.
3 weeks agoCapital Market - Live
Corporate
Corporate
Bacil Pharma to review financial results at board meeting on October 14, 2026Bacil Pharma Limited will hold a board meeting on Wednesday, October 14, 2026, to consider and approve the unaudited financial results for the half-yearly and quarter ended September 30, 2026, according to a regulatory filing with the BSE Limited.
4 weeks agoCapital Market - Live
Corporate
Corporate
Bacil Pharma closes trading window for designated persons ahead of financial resultsBacil Pharma Limited informed the BSE Limited that the trading window for designated persons will be closed from October 1, 2026, until 48 hours after the conclusion of the Board of Directors meeting to consider the unaudited financial results for the quarter and half year ended September 30, 2026, with the date of the board meeting to be intimated separately.
1 month agoCapital Market - Live
Corporate
Corporate
Bacil Pharma will close its member register September 17-23 for its 39th AGMBacil Pharma Limited informed the BSE Limited that it will close its register of members for equity shares from September 17, 2026, to September 23, 2026, for the purpose of the company’s 39th Annual General Meeting scheduled on September 23, 2026, and that no dividend has been declared for the financial year 2025-2026.
2 months agoCapital Market - Live
Corporate
Corporate
Bacil Pharma to convene a board meeting August 29 to address annual meeting detailsBacil Pharma Limited will hold a board meeting on August 29, 2026, to discuss the notice for the 39th Annual General Meeting, approve the Director Report for the financial year 2025-2026, and fix the date, place, and timing of the 39th Annual General Meeting.
2 months agoCapital Market - Live
Corporate
Corporate
Bacil Pharma to convene board meetingBacil Pharma will hold a meeting of the Board of Directors of the Company on 9 July 2026.
4 months agoCapital Market - Live
Corporate
Corporate
Bacil Pharma to convene board meetingBacil Pharma will hold a meeting of the Board of Directors of the Company on 26 June 2026.
4 months agoCapital Market - Live
Earnings
Earnings
Bacil Pharma standalone net profit rises 3000.00% in the March 2026 quarterNet profit of Bacil Pharma rose 3000.00% to Rs 0.62 crore in the quarter ended March 2026 as against Rs 0.02 crore during the previous quarter ended March 2025. There were no Sales reported in the quarter ended March 2026 and during the previous quarter ended March 2025. For the full year,net profit rose 290.00% to Rs 1.56 crore in the year ended March 2026 as against Rs 0.40 crore during the previous year ended March 2025. There were no Sales reported in the year ended March 2026 and during the previous year ended March 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Bacil Pharma to conduct board meetingBacil Pharma will hold a meeting of the Board of Directors of the Company on 22 May 2026.
5 months agoCapital Market - Live
Earnings
Earnings
Bacil Pharma reports standalone net profit of Rs 0.04 crore in the December 2025 quarterNet profit of Bacil Pharma reported to Rs 0.04 crore in the quarter ended December 2025 as against net loss of Rs 0.06 crore during the previous quarter ended December 2024. There were no Sales reported in the quarter ended December 2025 and during the previous quarter ended December 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 77.69%, vs industry avg of 10.72%
Over the last 5 years, market share stayed at 0%